Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease
We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6)....
Main Authors: | Kazufumi Takamatsu, Satoshi Marumo, Motonari Fukui, Atsuko Hata |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-08-01
|
Series: | Journal of Microbiology, Immunology and Infection |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118217300750 |
Similar Items
-
A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment
by: Jui-Yi Chen, et al.
Published: (2020-02-01) -
Peramivir: A novel intravenous neuraminidase inhibitor for treatment of acute influenza infections
by: Malak eAlame, et al.
Published: (2016-03-01) -
Clinical Implications of Antiviral Resistance in Influenza
by: Timothy C. M. Li, et al.
Published: (2015-09-01) -
INFLUENZA. DIAGNOSTICS, STRATEGY FOR SELECTION OF ANTI-VIRALS
by: N. V. Orlova
Published: (2018-01-01) -
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies
by: Natalia A. Ilyushina, et al.
Published: (2019-11-01)